Investigational drug · Phase 3
Vatiquinone
Also called: PTC743
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Friedreich's Ataxia, Friedreich Ataxia, Inherited Mitochondrial Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
21
Any phase or sponsor naming "Vatiquinone"
First trial start
2022
Jun 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Vatiquinone", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Friedreich's Ataxia
- Friedreich Ataxia
- Inherited Mitochondrial Disease
Approved drugs for the same conditions: Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Vatiquinone" as an intervention, largest first.
- A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaPivotal-lookingCompleted
PTC TherapeuticsIndustry
NCT04577352 · 146 participants · Start Dec 17, 2020 · Primary completion Apr 4, 2023
Drug: Vatiquinone; Placebo · For: Friedreich Ataxia
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 14 sites in all
- A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich AtaxiaPivotal-lookingActive, not recruiting
PTC TherapeuticsIndustry
NCT05515536 · 130 participants · Start Dec 8, 2022 · Primary completion Dec 31, 2027
Drug: Vatiquinone · For: Friedreich Ataxia
Sites: Los Angeles, California; Gainesville, Florida; Tampa, Florida · 14 sites in all
- Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)Pivotal-lookingNot yet recruiting
PTC TherapeuticsIndustry
NCT07681713 · 120 participants (planned) · Start Aug 15, 2026 · Primary completion Mar 15, 2029
Drug: Vatiquinone · For: Friedreich's Ataxia
Sites: Los Angeles, California; Tampa, Florida; Iowa City, Iowa · 9 sites in all
- A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseasePivotal-lookingCompleted
PTC TherapeuticsIndustry
NCT05218655 · 101 participants · Start Jun 22, 2022 · Primary completion Apr 15, 2025
Drug: Vatiquinone · For: Inherited Mitochondrial Disease
Sites: La Jolla, California; Stanford, California; New Haven, Connecticut · 26 sites in all
Edison Pharmaceuticals IncIndustry
NCT02257983 · 77 participants · Start Oct 31, 2014 · Primary completion Nov 30, 2015
Drug: EPI-743; Placebo · For: Noise-induced Hearing Loss
Sites: Gainesville, Florida
- A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyPivotal-lookingTerminated
PTC TherapeuticsIndustry
NCT04378075 · 68 participants · Start Sep 28, 2020 · Primary completion Mar 18, 2023
Drug: Vatiquinone · For: Mitochondrial Diseases; Drug Resistant Epilepsy; Leigh Disease and 5 more
Sites: San Diego, California; Stanford, California; New Haven, Connecticut · 27 sites in all
PTC TherapeuticsIndustry
NCT01728064 · 60 participants (planned) · Start Dec 31, 2012 · Primary completion Oct 31, 2015
Drug: Placebo; EPI-743 400 mg and 1 more · For: Friedreich's Ataxia
Sites: Los Angeles, California; Tampa, Florida; Philadelphia, Pennsylvania
PTC TherapeuticsIndustry
NCT01721733 · 35 participants · Start Oct 31, 2012 · Primary completion Feb 28, 2015
Drug: Placebo; EPI-743 15 mg/kg and 1 more · For: Leigh Syndrome
Sites: Palo Alto, California; Akron, Ohio; Houston, Texas · 4 sites in all
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
NCT01793090 · 30 participants · Start Jan 2013 · Primary completion Jul 2013
Drug: Epi-743 · For: Methylmalonic Aciduria and Homocystinuria,Cblc Type; Genetic Disease; Retinopathy
Sites: Rome, Italy
PTC TherapeuticsIndustry
NCT02352896 · 30 participants · Start Jan 31, 2014 · Primary completion Oct 30, 2023
Drug: EPI-743 · For: Leigh Syndrome
Sites: Stanford University, California; Akron, Ohio; Houston, Texas · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Enhanced Vatiquinone Bioavailability With Fatty Meals and Optimal Dosing Schedule.
Lee L, Murase K, Thoolen M, et al. · Biopharm Drug Dispos 2025
- Characterizing Population Pharmacokinetics of Vatiquinone in Healthy Volunteers and Patients with Friedreich's Ataxia.
Hu Y, Gao L, Lee L, et al. · Pharmaceuticals (Basel) 2025
- Evaluating the efficacy of vatiquinone in preclinical models of Leigh syndrome and GPX4 deficiency.
Kayser EB, Mulholland M, Olkhova EA, et al. · Orphanet J Rare Dis 2025
- Determination of Vatiquinone Drug-Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation.
Lee L, Okudaira N, Murase K, et al. · J Clin Pharmacol 2025
- Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone.
Lee L, Thoolen M, Ma J, et al. · Clin Pharmacol Drug Dev 2024
- Lack of Concentration-QTc Relationship and Cardiac Risk With Vatiquinone Therapeutic and Supratherapeutic Doses.
Lee L, Flach S, Xue H, et al. · Clin Pharmacol Drug Dev 2024
Also in development for Friedreich's Ataxia
- NomlabofuspCTI-1601Phase 32 trials
Larimar Therapeutics, Inc. · Friedreich Ataxia, Friedreich's Ataxia
- GV101Phase 22 trials
Graviton Bioscience Corporation · Friedreich's Ataxia, Weight Management
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.